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the restrictive formulary will still always be more costly
than the unrestrictive one. We then allow effectiveness
and costs to vary and derive equation to calculate the
cost of a restrictive formulary in those cases. We derive
the equations for patients with various distributions of
baseline severity. Last, we apply the equations and actual
effectiveness and cost data to the case of atypical anti-
psychotics where Ontario and British Columbia Provin-
cial formularies have mandated that risperidone be pre-
scribed before quetiapine or olanzapine. RESULT: The
cost of the restrictive status would range from $0.87–
0.97 per patient per day with mild symptoms treated
with risperidone, $2.65–3.30 for patients with moderate
symptoms and $5.14–5.73 for patients with severe symp-
toms. The range depends on effectiveness rates. Even if
all drug costs were equal and the efficacy rates were all
80 percent, the cost per patient per day for the restrictive
status of quetiapine would be $0.66–0.71, $1.12–1.41,
$1.67–2.26 for risperidone patient with mild moderate
and severe symptoms. CONCLUSION: To our knowl-
edge this is the first proof and practical application. Re-
strictions were removed in both provinces.
PMA5
A RISK ADJUSTMENT METHODOLOGY FOR 
CLAIMS DATA
Wilson P, Yuan Y, Dowse BT
IMS Health, Plymouth Meeting, PA, USA
OBJECTIVES: To develop a risk adjusted outcomes mea-
surement system that compensates for the lack of clinical
information in the claims data by dividing diseases into
different stages according to the severity at various stages
of the disease progression and the presence of other con-
ditions and procedures coded in the claims database.
METHODS: The data sources used were Medicare and
a large employer’s claims databases, which covered ap-
proximately 12 million and 130 thousand hospitali-
zations per year respectively. Rigorous data validation
processes were applied to ensure data validity. Our meth-
odology was based on the research completed by JS Gon-
nella, et.al,, (1987) “A Clinically Based Approach to
Measurement of Disease Severity”, sponsored by Na-
tional Center for Health Services Research, which classi-
fied diseases and combinations of diseases into different
stages according to severity. Our risk adjustment system
applied this approach to the principle diagnosis, second-
ary diagnoses and procedures coded in the claims data, to
derive severity measurements for each hospitalization. In
addition, we adjusted for the number of body systems in-
volved, patient age, gender and other factors. Outcomes
measurement included mortality, potentially avoidable
complications, length of hospital stay, total charges and
total cost. For each DRG group, logistic regression and
multiple regression models were developed from the
Medicare claims data to create risk adjusted norms.
Models were checked for statistical and clinical validity.
RESULTS: The model outputs were applied to the large
employer’s claims data to score each patient for each out-
come measurement. The results allowed for multi-dimen-
sional comparisons on quality measurements and re-
source utilization measurements for all the hospitals in
the large employer’s database. CONCLUSIONS: The
uniqueness of our methodology was that it adjusted for
severity of diseases at various stages and combinations of
diseases and number of body systems involved. It pro-
vided a more accurate means for risk adjustment than
currently available.
PMA6
THE REDUCTION OF SAMPLE SIZE FOR A
COST-EFFECTIVENESS TRIAL USING A
NEW METHOD: THE EIGHT CASES IN JAPAN
Kamae I, Yanagisawa S, Nakahara N
Kobe University, Kobe, Japan
At ISPOR’s Third Annual European Conference, we pre-
sented a new formula that can naturally extend the tradi-
tional formula for sample-size calculation of a clinical
trial, considering the cost-effectiveness ratios for two reg-
imens A and B. OBJECTIVE: According to the formula,
to explore applicability and validity of such a theoretical
framework in real clinical trials, and then show the bene-
fit which the new formula brings in terms of designing a
prospective cost-effectiveness trial. METHODS: We
searched and reviewed the published Japanese articles
these ten years that reported socioeconomic evaluation of
pharmaceuticals based on a clinical trial for two regi-
mens: a new treatment and an old one. Subsequently we
assessed the applicability and the validity of our formula
in the context of such reviewed articles, and then if the
formula could be applied, we calculated two sample
sizes: considering effect only vs. cost-effectiveness. RE-
SULTS: We reviewed eighteen Japanese articles which
conducted cost-effectiveness analysis using modeling or
retrospective cost evaluation after clinical trials except
one prospective study. Of these eight were selected as ap-
plicable for our formula. In all of them we found that the
sample size for one regimen, considering effect only vs.
cost-effectiveness, can be reduced such as 1534 to 5 at
the best, and 632 to 319 at the worst ratio. CONCLU-
SION: In the eight published Japanese studies, the sample
size of each clinical trial considering effect only could ac-
tually be reduced if such studies are to be designed in ad-
vance as a prospective cost-effectiveness trial considering
the difference of the cost-effectiveness ratios of two regi-
mens.
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OBJECTIVES: Measurement errors in independent vari-
ables may lead to attenuated estimates of their effects and
may contaminate estimates for other covariates in con-
ventional linear regression models (LRM). However, the
direction and magnitude of these biases are difficult to
determine theoretically. Measurement error is a serious
problem in health services research as health status is a
latent variable that can only be measured with error us-
ing proxy variables. This study empirically evaluated the
validity of LRM models in health outcomes research.
METHODS: SEMs with a latent health construct are
proposed and compared with LRM models to examine
the bias of measurement errors in general health status
using data from a study of the impact of pharmacist’s
consultation on both health outcomes and costs (KP/USC
study). Perceived health status at a given time point was
modeled as a latent variable measured by the multiple
scales of the SF-36. RESULTS: The latent health con-
struct with multiple scales of the SF-36 and its SEMs for
health outcomes and costs are empirically supported by
the KP/USC data. SEM estimations of the latent health
construct in both the measurement model and the struc-
tural model were all statistically significant with expected
signs. As predicted, LRM estimates for the SF-36 scales
were attenuated. However, there is no strong evidence
that LRM estimations of treatment effect were contami-
nated by the measurement errors in the SF-36 or that the
simultaneity between health outcomes and costs. CON-
CLUSIONS: Measurement errors in health status vari-
ables may result in attenuated estimates of health status
effects on patient outcomes. Fortunately, careful study
design can eliminate the contamination of treatment ef-
fect estimates due to errors in measuring health status.
Moreover, SEM methods can be used to control both at-
tenuation and resonation biases.
PMA8
DEVELOPMENT OF A CHRONIC DISEASE 
INDICATOR USING A MANAGED
CARE POPULATION
Malone DC1, Raebel MA2,3
1University of Arizona, Tucson, AZ, USA; 2Kaiser Permanente 
of Colorado, Denver, CO, USA; 3University of Colorado 
School of Pharmacy, Denver, CO, USA
OBJECTIVES: Accurate determination of disease preva-
lence in large patient populations is difficult. The objec-
tive of this research was to use pharmacy data to develop
an index that estimates the presence and number of
chronic diseases in a managed care population. METH-
ODS: An expert panel evaluated 246 specific medication
classes as to their likelihood to be indicative of a chronic
disease. Those classes identified were then compared
against medical records from two random samples of
persons 18 years of age or older continuously enrolled for
at least one year in a health maintenance organization.
One sample was drawn from all eligible persons (n 
137), while the other sample was restricted to individuals
50 years of age or greater (n  138). A cumulative num-
ber of chronic conditions was designated the chronic dis-
ease index (CDI). Sensitivity and specificity were calcu-
lated for those conditions with prevalence greater than
10% based upon medical record review. RESULTS: The
expert panel designated 54 drug classes as containing
medications used to treat chronic conditions. A total of
5640 medications were dispensed over a 1 year period for
the 275 subjects. The average total number of chronic
conditions via medical record review was 2.89  2.07,
compared to 1.33  1.21 chronic conditions estimated
by medication use. The CDI correlated well with the
number of chronic conditions found via record review
(r  0.735, p  0.0001). The specificity of pharmacy
records to indicate the presence of hypertension, dyslipi-
demia, depression, and diabetes was 79.9%, 99.0%,
90.2%, and 99.6%, respectively. The sensitivity was
90.9%, 49.9%, 77.5%, and 62.2% for hypertension,
dyslipidemia, depression, and diabetes, respectively. CON-
CLUSIONS: The CDI correlates well with documented
chronic conditions. Pharmacy data can be useful in iden-
tifying persons with diagnoses of hypertension, dyslipi-
demia, depression, and diabetes.
PMA9
BAYESIAN OR CLASSICAL DESIGN AND 
ANALYSIS: DOES IT MAKE A DIFFERENCE??
Bloom BS
University of Pennsylvania, Philadelphia, PA, USA
INTRODUCTION: The utility of research results is mea-
sured primarily by its effects on decisions. Underpinning
research are methods appropriate to the question or hy-
pothesis. The role of Classical and Bayesian approaches
remains in dispute in health services research. The goal of
this study was to determine if results differ when both
analytic techniques are used with the same dataset.
METHOD: We searched MEDLINE and related data-
bases for English-language articles published 1 January
1978 through 31 August 1999. We combined Bayesian
and Classical statistics search terms, and their variants,
with randomized control trials (RCTs) and meta analy-
ses. RESULTS: Searches found 18 studies in 14 publica-
tions that met all criteria for review—9 RCTs, 8 meta-anal-
yses and 1 epidemiological estimate. Statistical analyses
using both methods agreed in 5 RCTs, 4 meta-analyses,
and for the epidemiological estimates. For 4 RCTs where
results disagreed, Classical analysis the experimental in-
tervention was efficacious compared to the control and
Bayesian reanalysis concluded the experimental interven-
tion was not proven efficacious. Classical meta-analyses
of the four studies where results disagreed concluded the
experimental intervention was not better than the con-
trol; Bayesian reanalysis concluded the intervention was
efficacious. CONCLUSION: The conventional wisdom
that Classical and Bayesian methods will give similar an-
swers is not supported by this study. Disagreement on
many fundamental beliefs between Classical and Baye-
